0000899243-20-025640.txt : 20200917
0000899243-20-025640.hdr.sgml : 20200917
20200917214802
ACCESSION NUMBER: 0000899243-20-025640
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200917
DATE AS OF CHANGE: 20200917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galimi Francesco
CENTRAL INDEX KEY: 0001823996
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 201182671
MAIL ADDRESS:
STREET 1: 12930 VIA ESPERIA
CITY: DEL MAR
STATE: CA
ZIP: 92014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 BOYLSTON STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 500 BOYLSTON STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-15
0
0001720580
Adicet Bio, Inc.
ACET
0001823996
Galimi Francesco
C/O ADICET BIO, INC.
500 BOYLSTON STREET, 13TH FLOOR
BOSTON
MA
02116
0
1
0
0
Chief Medical Officer
Employee Stock Option (right to buy)
5.97
2020-09-15
4
A
0
128424
A
2029-10-15
Common Stock
128424
128424
D
Incentive Stock Option (right to buy)
16.11
2020-09-17
4
A
0
77269
0.00
A
2030-09-16
Common Stock
77269
77269
D
25% of the option will vest on September 23, 2020, and 1/36th of the remaining unvested option will vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.
Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."
1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.
Senior Vice President and Chief Medical Officer
/s/ Nick Harvey, Attorney-in-Fact for Francesco Galimi
2020-09-17